目的：通过对维吾尔族及汉族急性淋巴细胞白血病（ALL）患儿甲氨蝶呤（MTX）血药浓度监测结果的分析，为MTX不良反应的发生提供判断依据。方法：根据24 h MTX血药浓度监测结果，将28例（汉族 15 例，维吾尔族 13 例）接受大剂量MTX化疗的ALL患儿分为>10 μmol/L与≤10 μmol/L组；根据48 h MTX血药浓度监测结果分为>1.0 μmol/L与≤1.0 μmol/L组。采用酶放大免疫测定法对行MTX治疗的所有患儿给药后24 h及48 h血药浓度进行检测并观察不良反应发生情况。结果：不良反应发生率在不同24 h MTX血药浓度组间差异无统计学意义(P>0.05)；48 h MTX血药浓度>1.0 μmol/L组的消化道反应及黏膜损害发生率高于血药浓度≤1.0 μmol/L组 (P0.05)；汉族患儿24 h及48 h MTX血药浓度均高于维吾尔族(P<0.05)；除消化道反应外，汉族患儿肝功能异常、黏膜损害及骨髓抑制的发生率高于维吾尔族患儿 (P<0.05)。结论：24 h MTX血药浓度不能预测不良反应的发生，48 h MTX血药浓度对不良反应的发生有一定预测价值；24 h、48 h MTX血药浓度及不良反应发生率在维吾尔族及汉族间存在差异；MTX血药浓度监测结果可能对及时调整MTX用量，从而达到MTX个体化治疗具有重要意义。
Abstract
OBJECTIVE: To study blood concentrations of methotrexate (MTX) in Uyghur and Han children with acute lymphoblastic leukemia (ALL), and to provide criteria for judging the incidence of adverse effects of MTX. METHODS: Twenty-eight children with ALL (15 Han children and 13 Uyghur children), who received high-dose MTX chemotherapy, were divided into >10 μmol/L and ≤10 μmol/L groups according to 24-hour blood concentration of MTX, and divided into >1.0 μmol/L and ≤1.0 μmol/L groups according to 48-hour blood concentration of MTX. Enzyme multiplied immunoassay was used to measure blood concentrations of MTX in the MTX-treated children at 24 and 48 hours after MTX administration, and the adverse effects were observed. RESULTS: There was no significant difference in the incidence of adverse effects between the >10 μmol/L and ≤10 μmol/L groups (P>0.05). The >1.0 μmol/L group showed higher incidences of gastrointestinal reactions and mucosal injuries than the ≤1.0 μmol/L group (P0.05). Compared with Uyghur children, Han children showed higher 24- and 48-hour blood concentrations of MTX (P<0.05) and higher incidence of abnormal liver function, mucosal injuries, and bone marrow suppression (P<0.05). CONCLUSIONS: The 24-hour blood concentration of MTX cannot be used to predict the incidence of adverse effects in MTX chemotherapy, but 48-hour blood concentration of MTX is helpful in this regard. There are significant differences in 24- and 48-hour blood concentrations of MTX and the incidence of adverse effects between Uyghur and the Han children with ALL who receive MTX chemotherapy. Monitoring of blood MTX concentration maybe significant for timely adjustment of MTX dosage and individualized MTX chemotherapy.
关键词
急性淋巴细胞白血病 /
甲氨蝶呤 /
不良反应 /
血药浓度监测 /
患儿
Key words
Acute lymphoblastic leukemia /
Methotrexate /
Adverse effect /
Monitoring of blood MTX concentration /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］叶辉,顾龙君,陈静.儿童急性淋巴细胞白血病大剂量甲氨蝶呤治疗研究［J］.中华血液学杂志,2001,22 (7):385-386.
［2］韦润红,赵国兴,陈疏敏，程志.大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病耐受性临床研究［J］. 儿科药学杂志,2006,12(3):12-14.
［3］唐薇,张瑛,杨龙,张峻.66 例小儿急淋白血病大剂量甲氨蝶呤化疗血药浓度监测及个体化给药［J］. 中国现代应用药学,2006,23(6):508-510.
［4］顾龙君.儿童急性淋巴细胞白血病诊疗建议（第三次修订草案）［J］.中华儿科杂志,2006,44(5):392-395.
［5］陆爱东,张乐平,刘桂兰.大剂量甲氨蝶呤治疗急性淋巴细胞白血病的血药浓度研究［J］.实用儿科临床杂志,2004,19(1):36-38.
［6］Nathan PC, Whitcomb T, Wolters PL, Steinberg SM, Balis FM, Brouwers P, et al. Very highdosem ethotrexate ( 33.6 g /m2 ) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144 P［J］. Leuk Lymphoma, 2006, 47 (12): 2488-2504.
［7］詹其林,丁美琪,潘民,虞国慧，吴福红，邱晓星.大剂量甲氨蝶呤治疗急性淋巴细胞白血病和淋巴瘤副作用观察［J］.内科急危重症杂志,2008,14(4):207-209.
［8］刘莜梅,徐酉华,戴碧涛，宪莹，苏庸春. 大剂量甲氨蝶呤治疗儿童白血病毒副作用临床研究［J］.儿科药学杂志,2003,9 (5):45.
［9］ 徐卫群,汤永民,方澄清，宋华，石淑文，杨世隆，等. 大剂量甲氨蝶呤治疗儿童急性淋巴细胞白血病排泄延迟分析［J］. 中华血液学杂志,2005, 26(1):15-18.
［10］王玉成, 顾龙君. 甲氨蝶呤多聚谷氨酸盐在甲氨蝶呤治疗急性白血病中的作用及耐药机制研究进展［J］. 中国当代儿科杂志, 2000,2(5): 361-363.
［11］Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, et al. Methyleneterahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma［J］. Leuk Lymphoma, 2009, 50(6): 912-917.
［12］刘晶霞,陈洁平,谭文.亚甲基四氢叶酸还原酶基因多态性与急性淋巴细胞白血病患者甲氨喋呤化疗毒副反应的研究［J］.中国实验血液学杂志,2008,16(3):488-492.
［13］余慧,金润铭,白燕.急性淋巴细胞白血病患儿亚甲基四氢叶酸还原酶多态性与氨甲蝶呤毒副反应的研究［J］.中华儿科杂志,2005,43(4)：302.
［14］Treri-o LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects［J］. J Clin Oncol, 2009, 27(35): 5972-5978.
［15］张耀东,谭利娜,胡群,卫海燕,张小玲,熊昊.儿童急性淋巴细胞白血病免疫分型特征及其临床意义［J］.中国当代儿科杂志,2012, 14 (3): 188-191.
PDF(876 KB)
